Dr. Aysun Ertaş
Check-ups & DiagnosticsVerified
- 23+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Imaging (MRI, CT, PET)
Gallium-68 pet-ct
What a Gallium-68 PET-CT scan is, how receptor-targeted radiotracers detect neuroendocrine tumours and recurrent prostate cancer, what clinical evidence confirms, and how Turkish hospital costs compare with the UK, US, and Germany. This guide explains scanner preparation, uptake and scan duration, radiation safety, diagnostic report timelines, and how to verify qualified nuclear medicine facilities abroad.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Imaging (MRI, CT, PET)
- Hospitals
- 2
- Verified
- 2
- Price from
- Price on request
Verified surgeons for Gallium-68 PET-CT
2 doctors Compare doctors, ratings and prices — ask any of them for a free quote.
Uzm. Dr. Türkan Özer
Check-ups & DiagnosticsVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Gallium-68 PET-CT in Turkey: what it is and how it works
Gallium-68 PET-CT is an advanced hybrid imaging procedure combining Positron Emission Tomography (PET) with Computed Tomography (CT) to detect specific cellular receptors. Rather than measuring general glucose metabolism, this examination attaches a short-lived positron-emitting radioisotope, Gallium-68 (Ga-68), to targeting peptides. In clinical practice, these peptides primarily comprise DOTATATE for somatostatin receptors on neuroendocrine tumours, and PSMA-11 for prostate-specific membrane antigen on prostate cancer cells. Injected intravenously, the tracer binds directly to these receptor sites, pinpointing small lesions and nodal spread with high precision. Turkish hospitals provide these scans for international patients needing staging, re-staging, and therapy planning. For a broader overview of diagnostic services, explore our diagnostic checkup treatments in Turkey.
A Gallium-68 scan is an investigative examination rather than a surgical operation. It gives oncologists and urologists the biological mapping needed to plan targeted surgery, radiotherapy, or radioligand treatment. This guide explains how the technology works, clinical evidence, realistic results, costs across Turkey, the UK, the US, and Germany, and how to verify accredited centres abroad.
How does a gallium-68 PET-CT scan detect cellular changes?
The scan follows an exact radiopharmacy and scanning sequence. Gallium-68 is eluted from a Germanium-68/Gallium-68 generator or produced in a medical cyclotron before being compounded with the targeting peptide. Because the isotope has a physical half-life of approximately 68 minutes, each dose must be synthesised, quality-verified, and injected on a tight schedule.
After intravenous injection, the patient rests quietly in an uptake room for 45 to 60 minutes while the tracer circulates and binds to cellular receptors. The patient then empties their bladder and lies on the scanner bed. The hybrid machine performs a low-dose anatomical CT followed by the PET acquisition, which detects pairs of 511 keV gamma rays from positron annihilation. Advanced software fuses the structural CT images with metabolic PET data, calculating standardised uptake values (SUVmax) to measure receptor density.
Does gallium-68 PET-CT actually work? Clinical evidence and accuracy
Yes. International bodies including the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) endorse Gallium-68 imaging for established indications. Prospective trials confirm that Gallium-68 DOTATATE achieves sensitivity and specificity above 90% for well-differentiated neuroendocrine tumours (NETs), identifying nodal and bone metastases that standard CT, MRI, and OctreoScan examinations miss.
For prostate cancer, Gallium-68 PSMA has reshaped management in biochemical recurrence—when blood prostate-specific antigen (PSA) rises after prostatectomy or radiotherapy. Studies show PSMA PET-CT detects recurrent lesions at serum PSA levels below 0.5 ng/mL, altering clinical treatment plans in over half of cases. However, lesions that do not express the target receptor—such as dedifferentiated neuroendocrine carcinomas or certain neuroendocrine prostate variants—will not show tracer uptake. A nuclear medicine physician must review prior histology to confirm Gallium-68 suits your diagnosis.
Gallium-68 PET-CT cost in Turkey compared with the UK, US and Germany
The figures below reflect approximate market price ranges for a complete Gallium-68 PET-CT scan, including tracer production, scanner time, and specialist reporting. These are estimated ranges rather than binding quotes, as prices vary with tracer type and whether diagnostic CT contrast is added.
| Country | Approximate cost range |
|---|---|
| Turkey | €1,200 – €2,800 |
| United Kingdom | €2,500 – €5,500 |
| United States | €4,000 – €10,000 |
| Germany | €2,200 – €5,000 |
What changes the price: on-site generator elution versus off-site delivery, the inclusion of contrast-enhanced CT, and dual-physician reporting. In Turkey, international packages typically cover the tracer, scan acquisition, joint reporting by a nuclear medicine physician and radiologist, English translation, digital DICOM files, and clinic transfers. Submit your records for a free quote with a tailored hospital price.
Gallium-68 PET-CT compared with standard FDG scans and MRI
Selecting the appropriate imaging method depends on tumour biology, cellular differentiation, and clinical objectives.
| Diagnostic technique | Best suited to | Typical limits |
|---|---|---|
| Gallium-68 PET-CT (DOTATATE / PSMA) | Neuroendocrine tumours expressing somatostatin receptors, biochemical recurrence of prostate cancer | Higher tracer production cost; cannot assess tumours lacking target receptor expression |
| 18F-FDG PET-CT | High-grade, rapidly metabolising tumours, dedifferentiated neuroendocrine cancers, lymphoma | Low sensitivity for slow-growing, well-differentiated tumours or low-grade prostate cancer |
| Multiparametric MRI (mpMRI) | Local soft-tissue staging, anatomical prostate definition, liver metastasis structural detail | Lacks whole-body systemic receptor tracking; misses small distant bone or nodal metastases |
While 18F-FDG detects high glucose turnover in fast-growing malignancies, it often misses indolent neuroendocrine or prostate tumours with low metabolic rates. Multiparametric MRI provides detailed soft-tissue anatomy within the pelvis or liver, but cannot survey the whole body for distant bone or lymph node metastases. Clinicians frequently pair MRI with whole-body Gallium-68 imaging for comprehensive staging.
Which conditions and tumour types does gallium-68 imaging evaluate?
Gallium-68 scans primarily address two oncology disciplines, each using a distinct peptide conjugate:
- Neuroendocrine Tumours (NETs): Using Gallium-68 DOTATATE, DOTATOC, or DOTANOC, the scan maps carcinoid tumours, gastroenteropancreatic NETs, pheochromocytomas, and paragangliomas expressing somatostatin receptors. It also assesses eligibility for Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium-177.
- Prostate Cancer: Using Gallium-68 PSMA-11, the scan identifies primary nodal spread in high-risk patients and pinpoints recurrence when PSA rises after treatment. It also determines suitability for Lu-177 PSMA radioligand therapy.
- Other Indications: Selected clinics evaluate cardiac sarcoidosis or rare endocrine lesions. For routine non-oncological diagnostics such as breast screening, see our guide to mammography.
Gallium-68 PET-CT before and after: what do scan results actually show?
Evaluating a Gallium-68 PET-CT before and after involves tracking cellular receptor activity over time rather than physical shape changes. A baseline scan records tumour distribution and baseline SUVmax values before intervention. A follow-up scan, usually three to six months after surgery, radiotherapy, or radioligand treatment, assesses therapy response.
When reviewing your scan results, keep clinical distinctions in mind:
- What the scan shows: Discrete foci of intense tracer uptake standing out against normal tissue background, precise anatomical coordinates of small metastases down to 3–4 mm, and numerical SUV metrics comparing disease activity across visits.
- What the scan does not show: Imaging cannot distinguish malignant uptake from benign inflammation without clinical correlation, cannot detect tumours that lack somatostatin or PSMA receptors, and cannot replace a tissue biopsy for initial histological grading.
Who is an appropriate candidate for gallium-68 PET-CT?
Appropriate candidates are adult patients with confirmed or suspected neuroendocrine tumours or prostate cancer who require high-resolution staging, restaging, or treatment response monitoring. Patients with rising PSA following surgery or radiotherapy, and those considered for PRRT or Lu-177 PSMA therapy, are standard candidates.
The scan is less suitable or requires precautions in specific situations:
- Pregnancy: Ionising radiation from Gallium-68 and CT poses risks to an unborn child; scans are contraindicated in pregnant patients except in emergencies.
- Breastfeeding: Nursing mothers must express and discard milk for a set period following the scan until the tracer clears.
- Severe Claustrophobia: The gantry is a ring; patients with severe anxiety may need mild oral sedation to stay calm.
- Inability to Lie Flat: Patients must remain still on the table for 20–30 minutes. Severe back pain or breathing difficulties must be managed beforehand.
- Severe Contrast Allergy: If intravenous iodinated CT contrast is included, patients with severe contrast allergies or kidney failure require non-contrast CT protocols.
Your scan appointment, trip to Turkey and recovery milestones
Travelling to Turkey for a Gallium-68 PET-CT typically requires a stay of two to three days. This allows time for preliminary blood tests, tracer preparation, scanning, and multidisciplinary report translation. Learn more about planning medical travel on our how it works page.
The appointment proceeds through distinct stages:
- Pre-scan preparation: Fast for two to four hours before your appointment, but drink plain water to ensure proper hydration. Patients having DOTATATE scans coordinate the timing of long-acting somatostatin analogues with their oncologist to prevent receptor blockade.
- Tracer injection and uptake: An intravenous line is placed and the Gallium-68 tracer is infused. You rest in an uptake room for 45 to 60 minutes while the tracer binds to receptors, avoiding movement to minimise non-specific muscle uptake.
- The scan: After voiding your bladder to clear pelvic background radioactivity, you lie on the scanner bed. The machine performs a scout view, CT scan, and PET acquisition, taking 20 to 30 minutes in total.
- Immediate recovery: Physical recovery is immediate. You can eat, drink, and resume normal activity right away. Drinking one to two litres of water assists in clearing remaining tracer.
- Radiation clearance and travel: With a half-life of 68 minutes, over 96% of radioactivity decays within six hours. Avoid close contact with small children and pregnant women for 10 to 12 hours. Flying home the following day is safe.
Radiation safety and risks associated with gallium-68 imaging
A Gallium-68 PET-CT scan involves ionising radiation, but exposure remains within accepted international diagnostic safety levels established by the International Commission on Radiological Protection (ICRP) and the EANM.
The total radiation dose typically ranges from 4 to 9 millisieverts (mSv). The Gallium-68 tracer contributes approximately 3 to 5 mSv, while the CT component adds 2 to 4 mSv for low-dose attenuation correction (higher if diagnostic contrast CT is performed). This exposure is comparable to standard abdominal CT scans or two to three years of natural background radiation. Allergic reactions to Gallium-68 peptides are rare. If iodinated contrast is used for the CT portion, mild reactions such as nausea or warmth can occur, while serious reactions are rare and managed by hospital teams. Minor bruising at the injection site is possible.
How to choose a nuclear medicine department in Turkey and red flags
When selecting a nuclear medicine department in Turkey, verify clinical accreditations, equipment age, and specialist credentials:
- Certified Radiopharmacy: Ensure the clinic operates an on-site radiopharmacy or verified generator supply adhering to Good Radiopharmacy Practice (GRP).
- Modern PET-CT Systems: Look for time-of-flight (TOF) scanners that provide sharp lesion resolution at lower radiation doses.
- Dual-Specialist Reading: Scans should be co-interpreted by certified nuclear medicine physicians and diagnostic radiologists.
- Full Digital Records: The facility must provide uncompressed DICOM files on disc or cloud, plus an English report with detailed SUVmax figures.
Red flags include clinics quoting without seeing medical records, facilities unable to specify tracer types, failure to provide DICOM files, or no physician consultation. Check how the international booking process works and request a free quote to arrange your scan with an accredited hospital team.
Questions to ask the nuclear medicine team
- Which specific Gallium-68 conjugate (DOTATATE or PSMA-11) is scheduled for my scan?
- Does the protocol include diagnostic contrast-enhanced CT or low-dose CT?
- When will the translated English report and DICOM images be ready?
- Will a nuclear medicine specialist review the findings with me before departure?
Hospitals with Check-ups & Diagnostics in Turkey
Frequently asked questions
A gallium-68 PET-CT scan is a hybrid nuclear medicine examination combining positron emission tomography with computed tomography. It uses a short-lived radioisotope, gallium-68, linked to targeting peptides like DOTATATE or PSMA-11. These tracers bind directly to specific receptors on neuroendocrine or prostate cancer cells, providing precise anatomical and metabolic imaging.
Yes. Clinical trials and international guidelines from the EANM and SNMMI confirm that gallium-68 imaging offers high sensitivity and specificity exceeding 90% for neuroendocrine tumours and recurrent prostate cancer. It detects small metastases and low-level biochemical recurrences that standard CT, MRI, and older nuclear scans often miss.
In Turkey, a gallium-68 PET-CT scan typically costs between €1,200 and €2,800. In comparison, equivalent scans in the UK or Germany range from €2,200 to €5,500, and up to €10,000 in the US. The price covers tracer synthesis, scanner time, specialist reporting, and patient transfers.
Before and after scans compare tumour cellular activity across treatment intervals. The baseline scan maps initial disease location and standardised uptake values (SUVmax). A follow-up scan, performed three to six months after therapy, demonstrates whether tumours have shrunk, stabilised, or cleared, guiding ongoing oncological decisions.
Physical recovery is immediate. Because no general anaesthesia or surgical incision is involved, you can resume normal eating, drinking, and walking straight after the scan. Drinking plenty of water during the afternoon helps your kidneys filter and flush out the remaining radiotracer.
The scan itself does not cause pain. The only slight discomfort is the insertion of an intravenous cannula in your arm for tracer administration. Lying still on the scanner table for 20 to 30 minutes can feel firm, but cushions and supports are provided for comfort.
Gallium-68 has a physical half-life of roughly 68 minutes. More than 96% of the injected radioactivity decays naturally within six hours. Drinking water accelerates urinary clearance, and radiation levels return to negligible background levels within less than 24 hours.
Yes. The radiation dose from a gallium-68 PET-CT scan averages 4 to 9 mSv, which is comparable to standard diagnostic CT examinations. Adverse reactions to the peptide tracer are exceedingly rare. Precautions are required for pregnant or breastfeeding women, which should be discussed with the team.
Gallium-68 targets specific surface receptors on neuroendocrine tumours and prostate cancer cells, making it far more sensitive for these specific conditions. Standard 18F-FDG PET relies on glucose consumption, which works well for aggressive, high-grade cancers but often misses slow-growing, well-differentiated tumours.
A stay of two to three days is usually sufficient. This allows time for arrival, initial blood tests and clinical verification, the scanning appointment, and receipt of the translated English report and digital DICOM images before your return flight home.
Patient stories